Recent approval of swine flu vaccine’s by top pharmaceutical companies GlaxoSmithKline (GSK), Novartis (NVS) and Baxter International (BAX) to help ease influenza pandemic.

Top pharmaceutical companies in conjunction with wealthy nations are to help prevent the spread of the swine flu virus in under developed nations.

With the Swine Flu Virus now a global pandemic and other top biotech companies developing a swine flu vaccine, Vanguard Pharmaceutical’s has been recruited to distribute and promote a natural alternative to these scientific solutions.

With advanced orders from the UK government for over 60 million doses of its swine flu vaccine, GlaxoSmithKline UK is preparing to sell £3bn worth of swine flu drugs this year. Glaxo is Britain’s biggest pharmaceutical supplier and has deals with world governments for its antiviral treatment Relenza, which can relieve swine flu symptoms. Is that good enough to consider this company as an investment option?

Baxter International completed the production of its first commercial batches of CELVAPAN swine flu vaccine in late July and is discussing plans for distribution with national health authorities, subject to obtaining appropriate authorizations. Due to the global scale of the swine flu pandemic, Baxter has partnered with top pharmaceutical companies to enhance their potential product offerings.